Bankruptcy: Bright Green Corp
Form Type: 8-K
Filing Date: 2025-03-21
Corporate Action: Bankruptcy
Type: Update
Accession Number: 000149315225011097
Filing Summary: Bright Green Corporation filed a voluntary petition under Chapter 11 in the U.S. Bankruptcy Court for the District of New Mexico on February 22, 2025. The company is operating as a debtor-in-possession. On March 17, 2025, it filed a proposed Chapter 11 Plan of Reorganization and a related Disclosure Statement with the court. The Proposed Plan details the restructuring process and the events leading up to the bankruptcy. A press release regarding these filings was issued on March 21, 2025. The company cautions shareholders about the speculative nature of trading its securities during the bankruptcy process, noting potential risks and uncertainties associated with the restructuring efforts and the approval process by the Bankruptcy Court.
Document Link: View Document
Additional details:
Item Date: 2025-03-17
Chapter 11 Case Filed: 2025-02-22
Proposed Plan Date: 2025-03-17
Press Release Date: 2025-03-21
Exhibit 99 1: Chapter 11 Plan of Reorganization, dated March 17, 2025
Exhibit 99 2: Disclosure Statement, dated March 17, 2025
Exhibit 99 3: Press Release, dated March 21, 2025
Form Type: 8-K
Filing Date: 2025-02-27
Corporate Action: Bankruptcy
Type: New
Accession Number: 000149315225008512
Filing Summary: On February 24, 2025, Bright Green Corp filed a Form 8-K to report material developments related to its Chapter 11 bankruptcy filing and restructuring efforts. The company entered a Restructuring Support Agreement (RSA) with its majority shareholder, Lynn Stockwell, to implement a prepackaged restructuring. This includes an agreement to voluntarily withdraw all Cannabis-related renewal applications. The restructuring plan entails the establishment of a $6,500,000 Exit Facility to fund working capital, paying allowed administrative claims in cash, and restructuring debts through a combination of cash and equity distributions post-reverse stock split. A significant aspect of the plan is the anticipated conversion of a portion of the debt into common stock and the renaming of the company to Drugs Made In America Corp. The company plans to involve federal agencies in research and engage franchisees for facility management in controlled substance production. A petition for Chapter 11 relief was filed on February 22, 2025, with the aim of ongoing operations under bankruptcy court guidelines while seeking acceptance of the restructuring plan from the majority of its general unsecured creditors. The filing cautioned investors about the speculative nature of trading in company securities due to ongoing restructuring complexities.
Document Link: View Document
Additional details:
Item 1 01: Material Definitive Agreement
Item 1 03: Bankruptcy or Receivership
Restructuring Support Agreement Amendment Date: 2025-02-24
Exit Facility Amount: 6500000
Dilution: No dilution to holdings post-reverse split
Reverse Split Ratio: 50-1
Form Type: 8-K
Filing Date: 2025-01-28
Corporate Action: Bankruptcy
Type: New
Accession Number: 000149315225003865
Filing Summary: Bright Green Corporation entered into a Restructuring Support Agreement on January 21, 2025, with its major shareholder, Lynn Stockwell. This agreement facilitates the company’s restructuring efforts in anticipation of filing a petition for Chapter 11 bankruptcy. It outlines various terms including the conversion of a $2,825,000 pre-petition secured note into shares of Series A Convertible Voting Preferred Stock and the establishment of a $5,400,000 Exit Facility for working capital needs. The agreement also stipulates a restructuring plan involving a reverse stock split at a ratio of 50-1 and issuance of common stock to unsecured creditors. The company plans to change its name to Drugs Made In America Corp. and seeks to organize a joint venture to research plant-based controlled substances. A press release announcing this agreement was issued on January 23, 2025, cautioning security holders about the speculative nature of trading during the bankruptcy proceedings. The restructuring will require a majority vote from general unsecured creditors and is subject to court approval.
Document Link: View Document
Additional details:
Item 1 Entry: Restructuring Support Agreement
Item 1 03 Details: On January 21, 2025, the Company entered into a Restructuring Support Agreement with Lynn Stockwell.
Note Amount: $2,825,000
Note Principal: $2,500,000
Note Interest Fees Costs: $325,000
Expected Dip Facility: $300,000
Exit Facility Amount: $5,400,000
Conversion Rate: 1 preferred share to 16 common shares
New Company Name: Drugs Made In America Corp.
Reverse Split Ratio: 50-1
Joint Venture Details: Research of all plant based controlled substances at the Grants, New Mexico facility.
Press Release Date: 2025-01-27
Comments
No comments yet. Be the first to comment!